Highlights
About
Phage-based Antimicrobial Resistance-sensitizing Solutions
Trobix Bio is an Israeli biotech company pioneering the field of human microbiome via its TBX™ technology platform, utilizing CRISPR, phage and synthetic biology to re-program specific activities in targeted microbiome bacteria and develop orally administered precision oncology therapeutics.
Targeting cumulative markets of over $4 billion, Trobix’s preclinical products, TBX201 and TBX301, are being developed to reduce severe diarrhea and colitis in patients receiving irinotecan or checkpoint inhibitors, respectively. Its products may allow physicians to complete more oncology treatments and improve cancer patients’ quality of life.
Trobix Bio is a spin-off company of Ramot, the technology-transfer company of Tel Aviv University.
Identity
| Name | Trobix Bio |
|---|---|
| Slug | trobix-bio |
| Type / kind | startup |
| Crunchbase ID | trobix-innovations-trobix-bio |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4Iiw-qMJDA |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Netanya |
| HQ address | HaMelacha St 45, Netanya, Israel |
Web & social
| Website | https://www.trobix.bio/cgi-sys/suspendedpage.cgi |
|---|---|
| https://www.linkedin.com/company/40967811 | |
| YouTube | https://www.youtube.com/channel/UCeVk8zmbxKHckr9Cc5kebVg |
Classifications
Funding
| Total raised | $8.2M |
|---|---|
| Current stage | Series A |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}